Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2015 Feb 11;15(7):420–427. doi: 10.1016/j.clml.2015.02.001

Figure 3.

Figure 3

Overall survival (OS). A. With a median follow-up of 51 months (range, 1–105), the median OS has not been reached. B. On MVA, ALC ≥30 X109/L was associated with a significantly shorter 5-year OS (78% vs 98%, p<0.001). C. On MVA, onset of SMN was associated with a significantly shorter 5-year OS (63% vs 96%, p<0.001).